bosentan anhydrous has been researched along with Down Syndrome in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crepaz, R; De Santis, S; Montanaro, D; Romeo, C | 1 |
| Chen, Y; Feng, Y; He, J; Ren, Y | 1 |
| He, F; Ren, R; Xiao, X | 1 |
| Yao, A | 1 |
| Berger, RM; Bouma, BJ; Duffels, MG; Hoendermis, ES; Mulder, BJ; van Dijk, AP; van Loon, RL; Vis, JC | 1 |
| Berger, RM; Bouma, BJ; Bresser, P; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Nieuwkerk, PT; van Dijk, AP; van Loon, RL; Vis, JC | 1 |
| Doherty, DR; Eipe, N; Lai, L | 1 |
| Franks, C; Hall, K; Kermeen, FD; McNeil, K; O'Brien, K; Radford, D; Seale, H | 1 |
| Berger, RM; Bouma, BJ; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Mulder, P; van Dijk, AP; Vis, JC | 1 |
| Argiento, P; Bossone, E; Calabrò, R; Correra, A; D'Alto, M; D'Andrea, A; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Scognamiglio, G; Vizza, CD | 1 |
| Clarke, B; Griffiths, L; Mahadevan, VS; Monfredi, O | 1 |
| D'Alto, M; Mahadevan, VS | 1 |
| Christopoulos, A; Kourouklis, S; Kyriakides, ZS; Liagkas, K; Paradellis, G | 1 |
1 review(s) available for bosentan anhydrous and Down Syndrome
| Article | Year |
|---|---|
Pulmonary arterial hypertension associated with congenital heart disease.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Comorbidity; Down Syndrome; Eisenmenger Complex; Endothelium, Vascular; Epoprostenol; Health Behavior; Heart Defects, Congenital; Heart Transplantation; Humans; Hypertension, Pulmonary; Lung Transplantation; Oxygen Inhalation Therapy; Phosphodiesterase 5 Inhibitors; Piperazines; Practice Guidelines as Topic; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thrombosis | 2012 |
1 trial(s) available for bosentan anhydrous and Down Syndrome
| Article | Year |
|---|---|
Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
11 other study(ies) available for bosentan anhydrous and Down Syndrome
| Article | Year |
|---|---|
Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Eisenmenger Complex; Exercise Test; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Male; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2013 |
Bosentan treatment for pulmonary arterial hypertension due to patent ductus arteriosus and Down's syndrome in an infant.
Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Infant; Male; Sulfonamides; Treatment Outcome | 2014 |
Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome.
Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Heart Septal Defects; Humans; Hypertension, Pulmonary; Infant; Male; Mitral Valve Insufficiency; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Medical treatment for an adult patient with eisenmenger syndrome. A case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Eisenmenger Complex; Endothelin Receptor Antagonists; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Sulfonamides | 2015 |
Down patients with Eisenmenger syndrome: is bosentan treatment an option?
Topics: Adult; Bosentan; Down Syndrome; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Probability; Quality of Life; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Severe pulmonary hypertension and adenotonsillectomy in a child with Trisomy-21 and obstructive sleep apnea.
Topics: Adenoidectomy; Anesthetics, Intravenous; Anticoagulants; Antihypertensive Agents; Bosentan; Child; Down Syndrome; Elective Surgical Procedures; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Intubation, Intratracheal; Piperazines; Piperidines; Propofol; Purines; Remifentanil; Severity of Illness Index; Sildenafil Citrate; Sleep Apnea, Obstructive; Sulfonamides; Sulfones; Tonsillectomy; Treatment Outcome; Vasodilator Agents; Warfarin | 2009 |
Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
Topics: Adult; Antihypertensive Agents; Bosentan; Confidence Intervals; Down Syndrome; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Heart Defects, Congenital; Humans; Hypertension; Male; Prospective Studies; Pulmonary Artery; Sulfonamides; Time Factors; Walking | 2010 |
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Survival Rate; Time Factors | 2013 |
Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Topics: Adult; Aged; Alanine Transaminase; Antihypertensive Agents; Aspartate Aminotransferases; Bosentan; Down Syndrome; Exercise Tolerance; Female; Heart Defects, Congenital; Hemoglobins; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen; Retrospective Studies; Sex Factors; Sulfonamides | 2011 |
Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Down Syndrome; Echocardiography, Doppler; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome | 2006 |